newsfilter
← Latest News
PR Newswire·

INVESTIGATION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics

  • Faruqi & Faruqi, LLP is investigating potential securities claims against Tvardi Therapeutics, Inc. (NASDAQ: TVRD).
  • Tvardi shares fell more than 80% on Monday, October 13, 2025, following disappointing preliminary data from the Phase 2 REVERT clinical trial.
  • The trial evaluated TTI-101 for idiopathic pulmonary fibrosis but failed to meet its goals regarding safety, pharmacokinetics, and exploratory efficacy outcomes.
  • Preliminary data showed similar baseline characteristics across treatment arms except for percent predicted Forced Vital Capacity (FVC), which was lower in placebo-treated patients.
  • Investors who suffered significant losses in Tvardi stock or options are encouraged to contact Senior Partner James (Josh) Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310).
  • Additional information regarding the investigation is available at www.faruqilaw.com/TVRD or via the firm's website www.faruqilaw.com.